{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:43:06Z","timestamp":1792611786506,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10072-026-08893-w","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:22:37Z","timestamp":1772248957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The evolving landscape of amyloid-targeting therapies in Alzheimer\u2019s disease: progress and challenges"],"prefix":"10.1007","volume":"47","author":[{"given":"Binbin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-8952","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"10043","key":"8893_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer\u2019s disease. Lancet 388(10043):505\u201317","journal-title":"Lancet"},{"issue":"5","key":"8893_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Collaborators GDF","year":"2019","unstructured":"Collaborators GDF (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459\u2013480","journal-title":"Lancet Neurol"},{"issue":"10258","key":"8893_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"Collaborators GDF","year":"2020","unstructured":"Collaborators GDF (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204\u20131222","journal-title":"Lancet"},{"issue":"1","key":"8893_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","volume":"13","author":"A Wimo","year":"2017","unstructured":"Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, J\u00f6nsson L, Liu Z, Prince M (2017) The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 13(1):1\u20137","journal-title":"Alzheimers Dement"},{"issue":"2","key":"8893_CR5","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GDF Collaborators","year":"2022","unstructured":"Collaborators GDF (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105\u2013e125","journal-title":"Lancet Public Health"},{"issue":"11","key":"8893_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41582-018-0070-3","volume":"14","author":"M Kivipelto","year":"2018","unstructured":"Kivipelto M, Mangialasche F, Ngandu T (2018) Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol 14(11):653\u2013666","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"8893_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.scib.2025.03.023","volume":"70","author":"T Wei","year":"2025","unstructured":"Wei T, Zhou J, Wang Z, Liu X, Mi Y, Zhao Y, Xing Y, Zhao B, Zhou S, Liu Y, Liu Y, Tang Y (2025) Coupled sleep rhythm disruption predicts cognitive decline in Alzheimer\u2019s disease. Sci Bull (Beijing) 70(9):1491\u20131503","journal-title":"Sci Bull (Beijing)"},{"issue":"6","key":"8893_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/joim.13227","volume":"289","author":"I Lisko","year":"2021","unstructured":"Lisko I, Kulmala J, Annetorp M, Ngandu T, Mangialasche F, Kivipelto M (2021) How can dementia and disability be prevented in older adults: where are we today and where are we going? J Intern Med 289(6):807\u2013830","journal-title":"J Intern Med"},{"issue":"2","key":"8893_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179(2):312\u2013339","journal-title":"Cell"},{"key":"8893_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-981-32-9358-8_16","volume":"1184","author":"G Gallardo","year":"2019","unstructured":"Gallardo G, Holtzman DM (2019) Amyloid-\u03b2 and Tau at the crossroads of alzheimer\u2019s disease. Adv Exp Med Biol 1184:187\u2013203","journal-title":"Adv Exp Med Biol"},{"issue":"s1","key":"8893_CR11","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline EN, Bicca MA, Viola KL, Klein WL (2018) The Amyloid-\u03b2 oligomer hypothesis: beginning of the third decade. J Alzheimers Dis 64(s1):S567\u2013s610","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"8893_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/JAD-181300","volume":"68","author":"RE Becker","year":"2019","unstructured":"Becker RE, Greig NH (2019) Can we prevent dementia and not prevent neurons from dying? J Alzheimers Dis 68(2):489\u2013492","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"8893_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2174\/1871527316666170113120853","volume":"16","author":"SD Skaper","year":"2017","unstructured":"Skaper SD, Facci L, Zusso M, Giusti P (2017) Synaptic plasticity, dementia and alzheimer disease. CNS Neurol Disord Drug Targets 16(3):220\u2013233","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"8893_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2011.07.052","volume":"1415","author":"PH Reddy","year":"2011","unstructured":"Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer\u2019s disease. Brain Res 1415:136\u2009\u2212\u200948","journal-title":"Brain Res"},{"issue":"12","key":"8893_CR15","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1007\/s12035-020-02084-0","volume":"57","author":"S Guha","year":"2020","unstructured":"Guha S, Johnson GVW, Nehrke K (2020) The crosstalk between pathological Tau phosphorylation and mitochondrial dysfunction as a key to understanding and treating alzheimer\u2019s disease. Mol Neurobiol 57(12):5103\u20135120","journal-title":"Mol Neurobiol"},{"issue":"10","key":"8893_CR16","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"146","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Robakis NK, H\u00f8ilund-Carlsen PF, Sensi SL, Vissel B (2023) The amyloid cascade hypothesis: an updated critical review. Brain 146(10):3969\u20133990","journal-title":"Brain"},{"issue":"1","key":"8893_CR17","first-page":"43","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb M, Tao W, Chen N (2024) Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis 15(1):43\u201373","journal-title":"Aging Dis"},{"issue":"2","key":"8893_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JAD-180802","volume":"68","author":"G Paroni","year":"2019","unstructured":"Paroni G, Bisceglia P, Seripa D (2019) Understanding the amyloid hypothesis in Alzheimer\u2019s disease. J Alzheimers Dis 68(2):493\u2013510","journal-title":"J Alzheimers Dis"},{"issue":"5580","key":"8893_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297(5580):353\u2013356","journal-title":"Science"},{"issue":"4","key":"8893_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","volume":"83","author":"CH van Dyck","year":"2018","unstructured":"van Dyck CH (2018) Anti-Amyloid-\u03b2 Monoclonal Antibodies for Alzheimer\u2019s Disease: Pitfalls and Promise. Biol Psychiatry 83(4):311\u2013319","journal-title":"Biol Psychiatry"},{"issue":"6","key":"8893_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40120-024-00664-z","volume":"13","author":"A Wicker","year":"2024","unstructured":"Wicker A, Shriram J, Decourt B, Sabbagh MN (2024) Passive anti-amyloid beta monoclonal antibodies: lessons learned over past 20 years. Neurol Ther 13(6):1571\u20131595","journal-title":"Neurol Ther"},{"issue":"6","key":"8893_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40266-022-00949-8","volume":"39","author":"EA Largent","year":"2022","unstructured":"Largent EA, Peterson A, Karlawish J, Lynch HF (2022) Aspiring to reasonableness in accelerated approval: anticipating and avoiding the next aducanumab. Drugs Aging 39(6):389\u2013400","journal-title":"Drugs Aging"},{"issue":"8","key":"8893_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40263-023-01021-8","volume":"37","author":"S Leisher","year":"2023","unstructured":"Leisher S, Bohorquez A, Gay M, Garcia V, Jones R, Baldaranov D, Rafii MS (2023) Amyloid-lowering monoclonal antibodies for the treatment of early Alzheimer\u2019s disease. CNS Drugs 37(8):671\u2013677","journal-title":"CNS Drugs"},{"issue":"6","key":"8893_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2023.11703","volume":"330","author":"GD Rabinovici","year":"2023","unstructured":"Rabinovici GD, La Joie R (2023) Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease. JAMA 330(6):507\u2013509","journal-title":"JAMA"},{"issue":"1","key":"8893_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/ADR-220079","volume":"7","author":"V Volloch","year":"2023","unstructured":"Volloch V, Rits-Volloch S (2023) The amyloid cascade hypothesis 2.0: generalization of the concept. J Alzheimers Dis Rep 7(1):21\u201335","journal-title":"J Alzheimers Dis Rep"},{"issue":"9","key":"8893_CR26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698\u2013712","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"8893_CR27","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, Cao Y, Li H (2021) Interaction between A\u03b2 and Tau in the pathogenesis of Alzheimer\u2019s disease. Int J Biol Sci 17(9):2181\u20132192","journal-title":"Int J Biol Sci"},{"issue":"1","key":"8893_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-024-08815-z","volume":"27","author":"X Zhuang","year":"2024","unstructured":"Zhuang X, Lin J, Song Y, Ban R, Zhao X, Xia Z, Wang Z, Zhang G (2024) The interplay between accumulation of Amyloid-Beta and Tau proteins, PANoptosis, and inflammation in Alzheimer\u2019s disease. Neuromolecular Med 27(1):2","journal-title":"Neuromolecular Med"},{"key":"8893_CR29","doi-asserted-by":"crossref","unstructured":"Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9(1):119\u201328","DOI":"10.1016\/S1474-4422(09)70299-6"},{"issue":"44","key":"8893_CR30","doi-asserted-by":"publisher","first-page":"29621","DOI":"10.1074\/jbc.R800015200","volume":"283","author":"SL Cole","year":"2008","unstructured":"Cole SL, Vassar R (2008) The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem 283(44):29621\u201329625","journal-title":"J Biol Chem"},{"key":"8893_CR31","doi-asserted-by":"publisher","unstructured":"Maia MA, Sousa E (2019) BACE-1 and \u03b3-secretase as therapeutic targets for Alzheimer\u2019s disease. Pharmaceuticals (Basel) 12(1):41. https:\/\/doi.org\/10.3390\/ph12010041","DOI":"10.3390\/ph12010041"},{"issue":"4","key":"8893_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12551-017-0271-9","volume":"9","author":"KL Stewart","year":"2017","unstructured":"Stewart KL, Radford SE (2017) Amyloid plaques beyond A\u03b2: a survey of the diverse modulators of amyloid aggregation. Biophys Rev 9(4):405\u2013419","journal-title":"Biophys Rev"},{"issue":"4","key":"8893_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","volume":"57","author":"R Rajmohan","year":"2017","unstructured":"Rajmohan R, Reddy PH (2017) Amyloid-beta and phosphorylated Tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons. J Alzheimers Dis 57(4):975\u2013999","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"8893_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molmed.2005.02.009","volume":"11","author":"FM LaFerla","year":"2005","unstructured":"LaFerla FM, Oddo S (2005) Alzheimer\u2019s disease: Abeta, Tau and synaptic dysfunction. Trends Mol Med 11(4):170\u2013176","journal-title":"Trends Mol Med"},{"issue":"11","key":"8893_CR35","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2174\/1389450123666220421124030","volume":"23","author":"Y Dai","year":"2022","unstructured":"Dai Y, Lei C, Zhang Z, Qi Y, Lao K, Gou X (2022) Amyloid-beta targeted therapeutic approaches for Alzheimer\u2019s disease: long road ahead. Curr Drug Targets 23(11):1040\u20131056","journal-title":"Curr Drug Targets"},{"issue":"4","key":"8893_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100102","volume":"12","author":"J Rosen","year":"2025","unstructured":"Rosen J, Jessen F (2025) Patient eligibility for amyloid-targeting immunotherapies in Alzheimer\u2019s disease. J Prev Alzheimers Dis 12(4):100102","journal-title":"J Prev Alzheimers Dis"},{"key":"8893_CR37","doi-asserted-by":"publisher","unstructured":"Merighi S, Nigro M, Travagli A, Gessi S (2022) Microglia and Alzheimer\u2019s disease. Int J Mol Sci 23(21):12990. https:\/\/doi.org\/10.3390\/ijms232112990","DOI":"10.3390\/ijms232112990"},{"key":"8893_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.07.003","volume":"61","author":"EE Spangenberg","year":"2017","unstructured":"Spangenberg EE, Green KN (2017) Inflammation in Alzheimer\u2019s disease: lessons learned from microglia-depletion models. Brain Behav Immun 61:1\u201311","journal-title":"Brain Behav Immun"},{"issue":"7618","key":"8893_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356","journal-title":"Nature"},{"issue":"6555","key":"8893_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1126\/science.abi6401","volume":"373","author":"DJ Selkoe","year":"2021","unstructured":"Selkoe DJ (2021) Treatments for Alzheimer\u2019s disease emerge. Science 373(6555):624\u2013626","journal-title":"Science"},{"issue":"2","key":"8893_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210","journal-title":"J Prev Alzheimers Dis"},{"key":"8893_CR42","volume":"2","author":"GP Morris","year":"2014","unstructured":"Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer\u2019s disease. Acta Neuropathol Commun 2:135","journal-title":"Acta Neuropathol Commun"},{"key":"8893_CR43","doi-asserted-by":"publisher","unstructured":"Rafii MS, Aisen PS (2025) Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nat Rev Neurol\u00a021(9):490\u2013498. https:\/\/doi.org\/10.1038\/s41582-025-01123-5","DOI":"10.1038\/s41582-025-01123-5"},{"issue":"s1","key":"8893_CR44","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.3233\/JAD-179921","volume":"64","author":"CX Gong","year":"2018","unstructured":"Gong CX, Liu F, Iqbal K (2018) Multifactorial hypothesis and multi-targets for Alzheimer\u2019s disease. J Alzheimers Dis 64(s1):S107-s117","journal-title":"J Alzheimers Dis"},{"key":"8893_CR45","doi-asserted-by":"crossref","unstructured":"Aisen PS, Cummings J, Jack CR Jr., Morris JC, Sperling R, Fr\u00f6lich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B (2017) On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther 9(1):60","DOI":"10.1186\/s13195-017-0283-5"},{"issue":"19","key":"8893_CR46","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2174\/0115680266295495240415114919","volume":"24","author":"M Patwekar","year":"2024","unstructured":"Patwekar M, Patwekar F, Khan S, Sharma R, Kumar D (2024) Navigating the Alzheimer\u2019s treatment landscape: unraveling amyloid-beta complexities and pioneering precision medicine approaches. Curr Top Med Chem 24(19):1665\u20131682","journal-title":"Curr Top Med Chem"},{"key":"8893_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.837649","volume":"14","author":"CX Gong","year":"2022","unstructured":"Gong CX, Dai CL, Liu F, Iqbal K (2022) Multi-targets: an unconventional drug development strategy for Alzheimer\u2019s Disease. Front Aging Neurosci 14:837649","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"8893_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbrc.2012.08.020","volume":"425","author":"GG Glenner","year":"2012","unstructured":"Glenner GG, Wong CW (2012) Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem Biophys Res Commun 425(3):534\u20139","journal-title":"Biochem Biophys Res Commun"},{"key":"8893_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pneurobio.2017.03.001","volume":"153","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Song W (2017) Islet amyloid polypeptide: another key molecule in Alzheimer\u2019s pathogenesis? Prog Neurobiol 153:100\u2013120","journal-title":"Prog Neurobiol"},{"issue":"3","key":"8893_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0896-6273(00)00051-9","volume":"27","author":"R Vassar","year":"2000","unstructured":"Vassar R, Citron M (2000) Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron 27(3):419\u2013422","journal-title":"Neuron"},{"key":"8893_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7039138","volume":"2020","author":"MS Uddin","year":"2020","unstructured":"Uddin MS, Kabir MT, Jeandet P, Mathew B, Ashraf GM, Perveen A, Bin-Jumah MN, Mousa SA, Abdel-Daim MM (2020) Novel anti-Alzheimer\u2019s therapeutic molecules targeting amyloid precursor protein processing. Oxid Med Cell Longev 2020:7039138","journal-title":"Oxid Med Cell Longev"},{"key":"8893_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1019412","volume":"14","author":"W Yao","year":"2022","unstructured":"Yao W, Yang H, Yang J (2022) Small-molecule drugs development for Alzheimer\u2019s disease. Front Aging Neurosci 14:1019412","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"8893_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14656566.2024.2438317","volume":"26","author":"D Antony","year":"2025","unstructured":"Antony D, Sheth P, Swenson A, Smoller C, Maguire K, Grossberg G (2025) Recent advances in Alzheimer\u2019s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein. Expert Opin Pharmacother 26(1):63\u201373","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"8893_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0089-7","volume":"6","author":"R Vassar","year":"2014","unstructured":"Vassar R (2014) BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimers Res Ther 6(9):89","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"8893_CR55","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM (2023) Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"12","key":"8893_CR56","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Aducanumab: first approval. Drugs 81(12):1437\u20131443","journal-title":"Drugs"},{"issue":"1","key":"8893_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussi\u00e8re T, Hamann S, Cameron TO, Weinreb PH (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep 8(1):6412","journal-title":"Sci Rep"},{"issue":"5","key":"8893_CR58","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/alz.13755","volume":"20","author":"T Chen","year":"2024","unstructured":"Chen T, O\u2019Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, Patel D, von Rosenstiel P, von Hehn C, Salloway S, Hock C, Nitsch RM, Haeberlein SB, Sandrock A, Singhal P (2024) Results from the long-term extension of PRIME: a randomized phase 1b trial of aducanumab. Alzheimers Dement 20(5):3406\u20133415","journal-title":"Alzheimers Dement"},{"issue":"10","key":"8893_CR59","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","volume":"181","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Cavazzoni P (2021) Approval of aducanumab for Alzheimer disease-the fda\u2019s perspective. JAMA Intern Med 181(10):1276\u20131278","journal-title":"JAMA Intern Med"},{"key":"8893_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-med-051022-043645","volume":"75","author":"JL Heidebrink","year":"2024","unstructured":"Heidebrink JL, Paulson HL (2024) Lessons learned from approval of aducanumab for alzheimer\u2019s disease. Annu Rev Med 75:99\u2013111","journal-title":"Annu Rev Med"},{"key":"8893_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1599048","volume":"16","author":"H Wang","year":"2025","unstructured":"Wang H, Pan J, Zhang M, Tan Z (2025) Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab\/donanemab) in the treatment of early Alzheimer\u2019s disease. Front Pharmacol 16:1599048","journal-title":"Front Pharmacol"},{"issue":"4","key":"8893_CR62","doi-asserted-by":"publisher","first-page":"771","DOI":"10.14283\/jpad.2023.123","volume":"10","author":"S Cohen","year":"2023","unstructured":"Cohen S, van Dyck CH, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer LD (2023) Lecanemab Clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 10(4):771\u2013777","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"8893_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160","volume":"12","author":"C Chen","year":"2025","unstructured":"Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, Ogawa T, Dash A, Irizarry M, Dhadda S, Kanekiyo M, Hersch S, Iwatsubo T (2025) Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 12(5):100160","journal-title":"J Prev Alzheimers Dis"},{"issue":"20","key":"8893_CR64","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS (2023) Two phase 3 trials of gantenerumab in early alzheimer\u2019s disease. N Engl J Med 389(20):1862\u20131876","journal-title":"N Engl J Med"},{"issue":"1","key":"8893_CR65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, Wang G, Singhal P, Budd Haeberlein S, Smirnakis K (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease. JAMA Neurol 79(1):13\u201321","journal-title":"JAMA Neurol"},{"issue":"2","key":"8893_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","volume":"32","author":"GE Vitek","year":"2023","unstructured":"Vitek GE, Decourt B, Sabbagh MN (2023) Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of alzheimer disease. Expert Opin Investig Drugs 32(2):89\u201394","journal-title":"Expert Opin Investig Drugs"},{"key":"8893_CR67","doi-asserted-by":"publisher","first-page":"394632023120983","DOI":"10.1177\/03946320231209839","volume":"37","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Chowdhury NS (2023) Novel anti-amyloid-beta (A\u03b2) monoclonal antibody Lecanemab for alzheimer\u2019s disease: A systematic review. Int J Immunopathol Pharmacol 37:3946320231209839","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"8893_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ (2022) Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther 14(1):191","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"8893_CR69","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/10600280231218253","volume":"58","author":"J Park","year":"2024","unstructured":"Park J, Simpson C, Patel K (2024) Lecanemab: a humanized monoclonal antibody for the treatment of early alzheimer disease. Ann Pharmacother 58(10):1045\u20131053","journal-title":"Ann Pharmacother"},{"key":"8893_CR70","doi-asserted-by":"publisher","unstructured":"Martins AC, Oshiro MY, Albericio F, de la Torre BG (2024) Food and Drug Administration (FDA) approvals of biological drugs in 2023. Biomedicines\u00a012(9):1992. https:\/\/doi.org\/10.3390\/biomedicines12091992","DOI":"10.3390\/biomedicines12091992"},{"key":"8893_CR71","doi-asserted-by":"publisher","unstructured":"Dodel R, Fr\u00f6lich L (2025) Donanemab for Alzheimer\u2019s disease: from preclinical research to the clinical application. Expert Rev Neurother\u00a025(10):1151\u20131163. https:\/\/doi.org\/10.1080\/14737175.2025.2546868","DOI":"10.1080\/14737175.2025.2546868"},{"issue":"18","key":"8893_CR72","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in early alzheimer\u2019s disease. N Engl J Med 384(18):1691\u20131704","journal-title":"N Engl J Med"},{"issue":"5","key":"8893_CR73","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, Battioui C, Engle SE, Biffi A, Svaldi D, Salloway S, Greenberg SM, Sperling RA, Mintun M, Brooks DA, Sims JR (2025) Amyloid-related imaging abnormalities with Donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol 82(5):461\u2013469","journal-title":"JAMA Neurol"},{"issue":"4","key":"8893_CR74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21(4):306\u2013318","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"8893_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH (2023) Neuroinflammation in alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46(1):1\u201317","journal-title":"Inflammation"},{"issue":"1","key":"8893_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W (2023) Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther 8(1):248","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"8893_CR77","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1016\/j.scib.2024.09.042","volume":"69","author":"J Shi","year":"2024","unstructured":"Shi J, Touchon J, Middleton LT, Rovira MB, Vassar R, Vellas B, Shen Y (2024) Now and future: strategies for diagnosis, prevention and therapies for alzheimer\u2019s disease. Sci Bull (Beijing) 69(23):3777\u20133784","journal-title":"Sci Bull (Beijing)"},{"key":"8893_CR78","doi-asserted-by":"crossref","unstructured":"Sperling RA, Jack CR Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement 7(4):367\u201385","DOI":"10.1016\/j.jalz.2011.05.2351"},{"issue":"10","key":"8893_CR79","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","volume":"34","author":"J Barakos","year":"2013","unstructured":"Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melan\u00e7on D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M (2013) MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 34(10):1958\u20131965","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"8893_CR80","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146(11):4414\u20134424","journal-title":"Brain"},{"issue":"1","key":"8893_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"issue":"2","key":"8893_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, Castrillo-Viguera C, Rubino I, Vijverberg E (2022) Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis 9(2):211\u2013220","journal-title":"J Prev Alzheimers Dis"},{"key":"8893_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","volume":"2","author":"C Carlson","year":"2016","unstructured":"Carlson C, Siemers E, Hake A, Case M, Hayduk R, Suhy J, Oh J, Barakos J (2016) Amyloid-related imaging abnormalities from trials of Solanezumab for Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2:75\u201385","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"8893_CR84","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14201","volume":"12","author":"L VandeVrede","year":"2020","unstructured":"VandeVrede L, Gibbs DM, Koestler M, La Joie R, Ljubenkov PA, Provost K, Soleimani-Meigooni D, Strom A, Tsoy E, Rabinovici GD, Boxer AL (2020) Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54\/\u03b54 patient treated with aducanumab. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring 12(1):e12101","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"1","key":"8893_CR85","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther 9(1):95","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"8893_CR86","first-page":"255","volume":"4","author":"S Budd Haeberlein","year":"2017","unstructured":"Budd Haeberlein S, O\u2019Gorman J, Chiao P, Bussi\u00e8re T, von Rosenstiel P, Tian Y, Zhu Y, von Hehn C, Gheuens S, Skordos L, Chen T, Sandrock A (2017) Clinical development of Aducanumab, an anti-A\u03b2 human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s disease. J Prev Alzheimers Dis 4(4):255\u2013263","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"8893_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther 13(1):80","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"8893_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0193-y","volume":"8","author":"A Ivanoiu","year":"2016","unstructured":"Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T (2016) Long-term safety and tolerability of bapineuzumab in patients with Alzheimer\u2019s disease in two phase 3 extension studies. Alzheimers Res Ther 8(1):24","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"8893_CR89","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JAD-160216","volume":"57","author":"N Ketter","year":"2017","unstructured":"Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, Arrighi HM (2017) Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate alzheimer\u2019s disease patients. J Alzheimers Dis 57(2):557\u2013573","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"8893_CR90","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F (2022) Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review. JAMA Neurol 79(3):291\u2013304","journal-title":"JAMA Neurol"},{"issue":"24","key":"8893_CR91","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1212\/WNL.0b013e3181e03844","volume":"74","author":"DT Laskowitz","year":"2010","unstructured":"Laskowitz DT, Kolls BJ (2010) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate alzheimer disease. Neurology 74(24):2026 author reply 2026-7","journal-title":"Neurology"},{"key":"8893_CR92","doi-asserted-by":"crossref","unstructured":"Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr., Melan\u00e7on D, Morris K, Ketter N, Liu E, Brashear HR (2016) Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry 87(1):106\u201312","DOI":"10.1136\/jnnp-2014-309493"},{"issue":"23","key":"8893_CR93","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1016\/j.scib.2024.09.005","volume":"69","author":"S Jin","year":"2024","unstructured":"Jin S, Lu W, Zhang J, Zhang L, Tao F, Zhang Y, Hu X, Liu Q (2024) The mechanisms, hallmarks, and therapies for brain aging and age-related dementia. Sci Bull (Beijing) 69(23):3756\u20133776","journal-title":"Sci Bull (Beijing)"},{"issue":"1","key":"8893_CR94","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-200868","volume":"78","author":"AM Pietroboni","year":"2020","unstructured":"Pietroboni AM, Colombi A, Carandini T, Scarpini E, Galimberti D, Bozzali M (2020) The role of amyloid-\u03b2 in white matter damage: possible common pathogenetic mechanisms in neurodegenerative and demyelinating diseases. J Alzheimers Dis 78(1):13\u201322","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"8893_CR95","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ (2020) Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16(1):30\u201342","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"8893_CR96","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1515\/revneuro-2018-0056","volume":"30","author":"X Liu","year":"2019","unstructured":"Liu X, Hou D, Lin F, Luo J, Xie J, Wang Y, Tian Y (2019) The role of neurovascular unit damage in the occurrence and development of alzheimer\u2019s disease. Rev Neurosci 30(5):477\u2013484","journal-title":"Rev Neurosci"},{"issue":"22","key":"8893_CR97","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1212\/WNL.0b013e3181bd6a46","volume":"73","author":"DF Broderick","year":"2009","unstructured":"Broderick DF, Schweitzer KJ, Wszolek ZK (2009) Vascular risk factors and dementia: how to move forward? Neurology 73(22):1934\u20131935","journal-title":"Neurology"},{"issue":"3","key":"8893_CR98","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3233\/JAD-2010-091663","volume":"20","author":"C Qiu","year":"2010","unstructured":"Qiu C, Xu W, Fratiglioni L (2010) Vascular and psychosocial factors in Alzheimer\u2019s disease: epidemiological evidence toward intervention. J Alzheimers Dis 20(3):689\u2013697","journal-title":"J Alzheimers Dis"},{"key":"8893_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107213","volume":"152","author":"F Khan","year":"2023","unstructured":"Khan F, Qiu H (2023) Amyloid-\u03b2: a potential mediator of aging-related vascular pathologies. Vascul Pharmacol 152:107213","journal-title":"Vascul Pharmacol"},{"issue":"11","key":"8893_CR100","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.4103\/1673-5374.335829","volume":"17","author":"YL Zhang","year":"2022","unstructured":"Zhang YL, Wang J, Zhang ZN, Su Q, Guo JH (2022) The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer\u2019s disease. Neural Regen Res 17(11):2355\u20132363","journal-title":"Neural Regen Res"},{"issue":"1","key":"8893_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00296-z","volume":"11","author":"TO Klyucherev","year":"2022","unstructured":"Klyucherev TO, Olszewski P, Shalimova AA, Chubarev VN, Tarasov VV, Attwood MM, Syv\u00e4nen S, Schi\u00f6th HB (2022) Advances in the development of new biomarkers for Alzheimer\u2019s disease. Transl Neurodegener 11(1):25","journal-title":"Transl Neurodegener"},{"key":"8893_CR102","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","volume":"94","author":"L Rice","year":"2017","unstructured":"Rice L, Bisdas S (2017) The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease-a systematic review. Eur J Radiol 94:16\u201324","journal-title":"Eur J Radiol"},{"issue":"2","key":"8893_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14536","volume":"21","author":"X Zhong","year":"2025","unstructured":"Zhong X, Wang Q, Yang M, Lin G, Yao K, Wu Z, Xu D, Zhou H, Chen B, Shi H, Zhang M, Shi X, Zeng Y, Lao J, Liang S, Li J, Liu Q, Liu H, Chen Y, Lin Y, Ouyang C, Lv J, Liang X, Cheng Y, Ran P, Gong B, Zhang B, Guo J, Zhang H, Liu S, Zhang J, Liu H, Ning Y (2025) Plasma p-tau217 and p-tau217\/A\u03b21\u201342 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: insights for research and clinical practice. Alzheimers Dement 21(2):e14536","journal-title":"Alzheimers Dement"},{"issue":"3","key":"8893_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70038","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, Xiao ZS, Chen X, Bu XL, Liu YH, Zeng F, Zhang L, Li A, Cai Y, Sun P, He Z, Dor\u00e9 V, Fripp J, Bourgeat P, Chen Q, Yu JT, Tang Y, Zetterberg H, Masters CL, Guo T, Wang YJ (2025) Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts. Alzheimers Dement 21(3):e70038","journal-title":"Alzheimers Dement"},{"issue":"8","key":"8893_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70469","volume":"21","author":"KAQ Cousins","year":"2025","unstructured":"Cousins KAQ, Korecka M, Wan Y, Vulaj A, Brown C, Tropea TF, Lee EB, Tosun D, Landau SM, Okonkwo OC, Mindt MR, Weiner MW, Irwin DJ, Wolk DA, Shaw LM (2025) Comparison of plasma p-tau217\/A\u03b242, p-tau217, and A\u03b242\/A\u03b240 biomarkers by race to detect Alzheimer\u2019s disease. Alzheimers Dement 21(8):e70469","journal-title":"Alzheimers Dement"},{"issue":"18","key":"8893_CR106","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","volume":"111","author":"H Hampel","year":"2023","unstructured":"Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O\u2019Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE (2023) Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape. Neuron 111(18):2781\u20132799","journal-title":"Neuron"},{"issue":"11","key":"8893_CR107","doi-asserted-by":"publisher","first-page":"8162","DOI":"10.1002\/alz.14199","volume":"20","author":"DM Rentz","year":"2024","unstructured":"Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, Matthews BR, Miller DS, Mahinrad S, Napoli S, Okhravi HR, Petersen RC, Siemers ER, Weber CJ, Weisman DC, Carrillo MC (2024) Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer\u2019s disease: navigating clinician-patient engagement. Alzheimers Dement 20(11):8162\u20138171","journal-title":"Alzheimers Dement"},{"key":"8893_CR108","doi-asserted-by":"publisher","unstructured":"Dias D, Socodato R (2025) Beyond amyloid and tau: the critical role of microglia in Alzheimer\u2019s disease therapeutics. Biomedicines\u00a013(2):279. https:\/\/doi.org\/10.3390\/biomedicines13020279","DOI":"10.3390\/biomedicines13020279"},{"issue":"4","key":"8893_CR109","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, Johnson KA, Aisen PS (2023) The AHEAD 3\u201345 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement 19(4):1227\u20131233","journal-title":"Alzheimers Dement"},{"issue":"9","key":"8893_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70662","volume":"21","author":"R Yaari","year":"2025","unstructured":"Yaari R, Holdridge KC, Williamson M, Wessels AM, Shcherbinin S, Kotari V, Reiman EM, Tariot PN, Alexander R, Langbaum JB, Sims JR (2025) Donanemab in preclinical Alzheimer\u2019s disease: screening and baseline data from TRAILBLAZER-ALZ 3. Alzheimers Dement 21(9):e70662","journal-title":"Alzheimers Dement"},{"issue":"1","key":"8893_CR111","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C (2017) The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement 13(1):8\u201319","journal-title":"Alzheimers Dement"},{"issue":"1","key":"8893_CR112","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","volume":"14","author":"BH Kim","year":"2025","unstructured":"Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M (2025) Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener 14(1):6","journal-title":"Transl Neurodegener"},{"issue":"s1","key":"8893_CR113","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JAD-240189","volume":"101","author":"K Noorda","year":"2024","unstructured":"Noorda K, Noorda K, Sabbagh MN, Bertelson J, Singer J, Decourt B (2024) Amyloid-directed antibodies: past, present, and future. J Alzheimers Dis 101(s1):S3-s22","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"8893_CR114","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14712598.2025.2463963","volume":"25","author":"F Panza","year":"2025","unstructured":"Panza F, Dibello V, Sardone R, Zupo R, Castellana F, Leccisotti I, Moretti MC, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Resta E, Lozupone M (2025) Successes and failures: the latest advances in the clinical development of amyloid-\u03b2-targeting monoclonal antibodies for treating Alzheimer\u2019s disease. Expert Opin Biol Ther 25(3):275\u2013283","journal-title":"Expert Opin Biol Ther"},{"issue":"s1","key":"8893_CR115","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.3233\/JAD-179907","volume":"64","author":"RM Nisbet","year":"2018","unstructured":"Nisbet RM, G\u00f6tz J (2018) Amyloid-\u03b2 and Tau in Alzheimer\u2019s disease: novel pathomechanisms and Non-Pharmacological treatment strategies. J Alzheimers Dis 64(s1):S517-s527","journal-title":"J Alzheimers Dis"},{"issue":"31","key":"8893_CR116","doi-asserted-by":"publisher","first-page":"13888","DOI":"10.1073\/pnas.1009038107","volume":"107","author":"J van Eersel","year":"2010","unstructured":"van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, G\u00f6tz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer\u2019s disease models. Proc Natl Acad Sci U S A 107(31):13888\u201393","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8893_CR117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4155\/ppa-2019-0003","volume":"8","author":"HE Lee","year":"2019","unstructured":"Lee HE, Lim D, Lee JY, Lim SM, Pae AN (2019) Development of tau-directed small molecule modulators for Alzheimer\u2019s disease: a recent patent review (2014\u20132018). Pharm Pat Anal 8(1):15\u201339","journal-title":"Pharm Pat Anal"},{"key":"8893_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.879021","volume":"14","author":"HM Blevins","year":"2022","unstructured":"Blevins HM, Xu Y, Biby S, Zhang S (2022) The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 14:879021","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"8893_CR119","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3233\/JAD-190357","volume":"72","author":"R Parodi-Rull\u00e1n","year":"2019","unstructured":"Parodi-Rull\u00e1n R, Sone JY, Fossati S (2019) Endothelial mitochondrial dysfunction in cerebral amyloid angiopathy and Alzheimer\u2019s disease. J Alzheimers Dis 72(4):1019\u20131039","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"8893_CR120","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamainternmed.2023.1749","volume":"183","author":"JC Arbanas","year":"2023","unstructured":"Arbanas JC, Damberg CL, Leng M, Harawa N, Sarkisian CA, Landon BE, Mafi JN (2023) Estimated annual spending on Lecanemab and its ancillary costs in the US medicare program. JAMA Intern Med 183(8):885\u2013889","journal-title":"JAMA Intern Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08893-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:02:08Z","timestamp":1774076528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08893-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["8893"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08893-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent to participate Ethical approval was not required for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"304"}}